Leucovorin (Folinic Acid): Indications and Dosing
Leucovorin is indicated for three primary scenarios: (1) rescue after high-dose methotrexate therapy, (2) treatment of folate deficiency when oral therapy is not feasible, and (3) combination with 5-fluorouracil in advanced colorectal cancer. The dosing varies dramatically based on indication, ranging from 15 mg every 6 hours for methotrexate rescue to 200-500 mg/m² for colorectal cancer protocols 1.
Methotrexate Rescue (High-Dose)
For high-dose methotrexate (12-15 g/m²), leucovorin rescue begins at 15 mg (approximately 10 mg/m²) every 6 hours for 10 doses, starting 24 hours after methotrexate infusion begins 1. This timing is critical—rescue delayed beyond 36 hours significantly increases toxicity risk 2.
Dose Adjustments Based on Methotrexate Levels:
- Normal elimination (MTX <0.2 micromolar at 72 hours): Continue standard 15 mg every 6 hours for 10 doses
- Delayed late elimination (MTX >0.2 micromolar at 72 hours): Continue 15 mg every 6 hours until MTX <0.05 micromolar
- Delayed early elimination or renal injury (MTX ≥50 micromolar at 24 hours OR ≥5 micromolar at 48 hours): Escalate to 150 mg IV every 3 hours until MTX <1 micromolar, then 15 mg every 3 hours until <0.05 micromolar 1
Critical pitfall: Patients with renal impairment require aggressive hydration, urinary alkalinization (pH ≥7.0), and close monitoring of fluid/electrolyte status alongside leucovorin therapy 1.
Methotrexate Toxicity (Low-Dose)
For hematologic toxicity from low-dose methotrexate (used in psoriasis, rheumatoid arthritis), administer folinic acid 10 mg/m² immediately when overdose is suspected or worrisome blood count decrements occur, then repeat every 6 hours 3. The effectiveness decreases as time from methotrexate administration increases, making immediate administration essential 3.
Recent evidence comparing 15 mg versus 25 mg every 6 hours in severe low-dose methotrexate toxicity showed no survival difference, with mortality remaining high (42-47%) regardless of leucovorin dose 4. This underscores that prevention through patient education about proper weekly (not daily) dosing is paramount, as most cases result from inadvertent daily administration 4.
Folate Supplementation During Methotrexate Therapy
For patients on chronic low-dose methotrexate (psoriasis, rheumatoid arthritis), prescribe folic acid 5 mg weekly or 1-5 mg daily (except on methotrexate dosing day) to reduce gastrointestinal and hepatic toxicity 5, 6, 7. This is distinct from leucovorin rescue—folic acid is preferred over folinic acid for routine supplementation due to cost, with no demonstrated superiority of folinic acid 7.
The evidence strongly supports that folate supplementation:
- Reduces liver enzyme elevations and methotrexate discontinuation rates by approximately 50% 8, 9
- Decreases gastrointestinal side effects without compromising efficacy 5, 8
- Does not reduce hematologic complications 7
Important caveat: Large doses of folate may theoretically reduce methotrexate efficacy, though clinical significance remains debated 6.
Colorectal Cancer (5-Fluorouracil Modulation)
Two FDA-approved regimens exist for advanced colorectal cancer 1:
- High-dose regimen: Leucovorin 200 mg/m² IV over ≥3 minutes, followed by 5-FU 370 mg/m² IV daily × 5 days
- Low-dose regimen: Leucovorin 20 mg/m² IV, followed by 5-FU 425 mg/m² IV daily × 5 days
Repeat cycles every 4 weeks for 2 courses, then every 4-5 weeks thereafter 1.
Modern NCCN protocols use different leucovorin dosing 10:
- FOLFOX/FOLFIRI regimens: Leucovorin 400 mg/m² (or levoleucovorin 200 mg/m²) IV over 2 hours on day 1, every 2 weeks
- Roswell-Park regimen: Leucovorin 500 mg/m² IV over 2 hours on days 1,8,15,22,29,36, every 8 weeks
- Weekly regimen: Leucovorin 20 mg/m² or 500 mg/m² depending on protocol
Critical administration detail: Never mix leucovorin and 5-FU in the same infusion—a precipitate will form 1.
Folate Deficiency (Megaloblastic Anemia)
Leucovorin is indicated for megaloblastic anemia due to folate deficiency only when oral therapy is not feasible 1. Specific dosing for this indication is not well-defined in the provided evidence, as oral folic acid is preferred when tolerated.
Key Clinical Pearls
- Route matters: Parenteral leucovorin is mandatory when gastrointestinal toxicity, nausea, or vomiting prevents oral absorption 1
- Never administer leucovorin intrathecally—this is explicitly contraindicated 1
- L-leucovorin is the active isomer: The racemic mixture (dl-leucovorin) contains inactive d-leucovorin that may interfere with transport and metabolism 11
- Monitor methotrexate levels daily during high-dose rescue to guide leucovorin duration 1